Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deana Nes

Rheumatology Emerson, NJ Doctor of Osteopathy

NPI 1851710040 CMS profile 6434434

466 Old Hook Rd Ste 1, Emerson, NJ 07630

Open in the dashboard

General payments

$7,227

384 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deana Nes of Emerson, NJ is reported in the CMS Open Payments database as having received $7,227 across 384 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,071 98
2024 General $1,855 96
2023 General $1,656 90
2022 General $957 54
2021 General $13 1
2020 General $266 18
2019 General $409 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deana Nes
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Deana Nes were reported at $2,071. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Deana Nes Rheumatology median Middle half National median
2019 $409 $744 $153–$2,687 $163
2020 $266 $462 $98–$2,027 $114
2021 $13 $531 $101–$2,153 $132
2022 $957 $627 $125–$2,303 $149
2023 $1,656 $741 $145–$2,524 $160
2024 $1,855 $830 $166–$2,660 $164
2025 $2,071 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $937 48 payments
  2. AbbVie, Inc. $847 49 payments
  3. Novartis Pharmaceuticals Corporation $750 37 payments
  4. UCB, Inc. $619 35 payments
  5. Janssen Biotech, Inc. $575 26 payments
  6. ANI Pharmaceuticals, Inc. $407 24 payments
  7. Lilly USA, LLC $307 20 payments
  8. Pfizer Inc. $307 21 payments
  9. Mallinckrodt Hospital Products Inc. $221 13 payments
  10. Fidia Pharma USA Inc. $219 3 payments
  11. Other $2,036 108 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,151 381 payments
  2. Education $75 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $648 36 payments
  2. COSENTYX $637 31 payments
  3. EVENITY $535 21 payments
  4. TREMFYA $471 19 payments
  5. Cimzia $373 22 payments
  6. XELJANZ $307 21 payments
  7. PURIFIED CORTROPHIN GEL $301 18 payments
  8. TALTZ $294 19 payments
  9. Bimzelx $247 13 payments
  10. SIMPONI ARIA $228 8 payments
  11. Other $3,970 226 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,732

Median for Rheumatology: 1,511

Drug cost

$835,326

Median for Rheumatology: $1,139,948

Branded share of claims

23%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 54 $397,667
Orencia Clickject Abatacept Brand 44 $288,969
Otezla Apremilast Brand 15 $71,074
Teriparatide Generic 16 $35,590
Hydroxychloroquine Sulfate Generic 212 $9,305
Diclofenac Sodium Generic 15 $6,782
Methotrexate Methotrexate Sodium Brand 211 $6,067
Colchicine Generic 21 $1,982
Prednisone Generic 281 $1,884
Lidocaine Generic 24 $1,874

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$213,813

Of which drugs: $126,872

Medicare patients

350

Average age 73

Services billed

23,946

247 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Osteoporosis 31%
Ischemic heart disease 23%
Diabetes 22%
Depression 20%
Cancer 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 15 1,320 $27,069
Injection, methylprednisolone acetate, 1 mg J1010 Office 26 1,124 $113

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $242
$242 — —
EVENITY
  • Amgen Inc. $172
$172 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $145
$145 — —
RINVOQ
  • AbbVie, Inc. $144
$144 — —
Korlym
  • Corcept Therapeutics $143
$143 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

384 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record